Jardiance Dosing Recommendations
Start Jardiance at 10 mg once daily in the morning, with or without food, and increase to 25 mg daily only if additional glycemic control is needed in patients with type 2 diabetes who tolerate the lower dose. 1
Standard Dosing
- Initial dose: 10 mg once daily (morning administration)
- Maximum dose: 25 mg once daily
- Administration: With or without food 1
The 10 mg dose is the evidence-based starting point tested in cardiovascular and renal outcomes trials. No dose titration is required for cardiovascular or renal risk reduction benefits—the 10 mg dose provides full cardioprotective effects. 2 Dose escalation to 25 mg serves only to enhance glucose lowering if glycemic targets are not met. 1
Renal Function Adjustments
For glycemic control:
- eGFR ≥45 mL/min/1.73 m²: No adjustment needed; use standard dosing
- eGFR 30-44 mL/min/1.73 m²: Can use, but glycemic efficacy is reduced (not recommended for glucose control alone) 2, 1
- eGFR <30 mL/min/1.73 m²: Not recommended for glycemic control—likely ineffective due to mechanism of action 1
For heart failure or cardiovascular indications:
- eGFR 20-29 mL/min/1.73 m²: Insufficient data to provide dosing recommendation 1
- eGFR <20 mL/min/1.73 m² (heart failure): Insufficient data 1
- Dialysis: Contraindicated 1
The FDA label emphasizes that glycemic efficacy decreases progressively with declining renal function. In clinical trials, HbA1c reductions were -0.6% with eGFR 60-90, -0.5% with eGFR 45-60, and only -0.2% with eGFR 30-45 mL/min/1.73 m². 1 However, cardiovascular and renal protective benefits persist even with moderate renal impairment. 3
Critical point: Assess renal function before initiating Jardiance and monitor as clinically indicated. 1 Pharmacokinetic studies show AUC increases by 66% in severe renal impairment, though this does not require dose adjustment per FDA guidance. 4
Hepatic Impairment
No dose adjustment is required for any degree of hepatic impairment (mild, moderate, or severe). 5
While empagliflozin exposure increases up to 1.7-fold in severe hepatic impairment (Child-Pugh Class C), this increase is considered clinically insignificant. 6, 5 The drug was well-tolerated across all hepatic impairment categories in pharmacokinetic studies. 5
Older Adults
No dose adjustment based on age alone. 1, 7
Empagliflozin demonstrates consistent cardiovascular benefits across age groups, including patients ≥75 years. 7 In the EMPA-REG OUTCOME trial, cardiovascular death hazard ratios were similar across age categories: 0.72 (age <65), 0.54 (age 65-75), and 0.55 (age ≥75). 7
Key precautions in older adults:
- Assess volume status before initiation—correct volume depletion first 1
- Monitor for hypotension and dehydration risk (2-10% incidence of volume-related adverse effects) 3
- Consider reducing or temporarily stopping diuretics if volume depletion is a concern 2
- Genitourinary infections occur more frequently in older adults 3
Critical Safety Considerations
Before initiating:
- Assess renal function (eGFR)
- Correct volume depletion if present
- Screen for risk factors: prior amputations, severe peripheral neuropathy, active foot ulcers 2
Discontinue at least 3 days before planned surgery to prevent postoperative ketoacidosis. 2
When combining with insulin or sulfonylureas:
- Consider reducing insulin dose by ~20% at initiation 2
- Wean or stop sulfonylurea if HbA1c is well-controlled or patient has history of hypoglycemia 2
Common Adverse Effects to Monitor
- Genital fungal infections: 2-10% (dose-dependent, more common in women and uncircumcised males) 3
- Urinary tract infections: 2-10% (higher in females) 3
- Euglycemic ketoacidosis: Rare but serious—can occur with glucose <250 mg/dL 1
- Volume depletion: Monitor in patients on diuretics or with baseline volume issues 2
Risk factors for ketoacidosis include: insulin deficiency, surgery, prolonged fasting, illness, missed insulin doses, alcohol abuse. 3 If suspected, discontinue immediately and treat urgently. 1